 MALVERN, Pa., Sept. 26, 2022 GLOBE NEWSWIRE -- Galera Therapeutics, Inc. Nasdaq: GRTX, a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that tumor outcomes data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis SOM and final data from its Phase 2 AESOP trial of avasopasem for chemoradiotherapy-induced esophagitis will be highlighted in two presentations at the upcoming 2022 American Society for Radiation Oncology ASTRO Annual Meeting, taking place October 23-26, 2022 in San Antonio, Texas. Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer. 